5:15 PM
 | 
Jan 20, 2012
 |  BC Extra  |  Company News

FDA panel votes against Prochieve

FDA's Reproductive Health Drugs Advisory Committee voted 13-4 that the benefit-risk profile of Prochieve vaginal progesterone gel from Columbia Laboratories Inc. (NASDAQ:CBRX) does not support its approval in reducing the risk of preterm birth in women...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >